GNR-055 for Hunter syndrome after standard enzyme treatment
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism, Mental health, Skin clinical trials.
This trial tests the safety and effectiveness of a study medicine called GNR-055 in people with Hunter syndrome (MPS II). It may help researchers learn whether the treatment improves outcomes and how the body handles the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a consent form and follow study instructions
- You have a confirmed diagnosis of Hunter syndrome (MPS II)
- You are either new to this treatment or have previously received standard enzyme therapy (idursulfase)
- Your doctor thinks it’s safe for you to have a lumbar puncture (a spinal fluid test)
- You do not have serious allergy to this drug (or its ingredients)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a follow-up study for people who already took JR-141 in an earlier trial for Hunter syndrome (MPS II). It checks how well the treatment works over the long term and monitors long-term safety.
This early-stage trial tests JR-446, a new treatment for MPS IIIB, a rare genetic disorder that affects the brain and body. The treatment is delivered directly into the fluid around the spinal cord and aims to slow or improve symptoms in young children.
This study tests a new gene therapy called JWK008 for adults with MPS type I. The goal is to see if it is safe and can help improve symptoms. You may be able to join if you are 18 or older and have not had serious side effects from enzyme replacement therapy.
This trial tests an experimental drug, JR-446, for children with Sanfilippo syndrome type B (MPS IIIB). The goal is to see if it is safe and can help with symptoms.
This trial compares a new treatment (tividenofusp alfa) to the current standard treatment (idursulfase) in children and young adults with MPS II. It’s looking to see which option works better and is safe, especially based on age and whether the disease affects the brain.
This study is for people with MPS II (Hunter syndrome) who have already completed a previous Denali study. It will test a drug called tividenofusp alfa (DNL310) over a longer period to see how safe it is and how well it works.
Hear when a new Mucopolysaccharidosis Type II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.